JPRN-UMIN000044863已完成未知
Safety and efficacy of first-line Osimertinib therapy including the frequency of drug-induced lung disease - Safety and efficacy of first-line Osimertinib therapy including the frequency of drug-induced lung disease
Kobe University Graduates School of Medicine0 个研究点目标入组 133 人开始时间: 2021年7月19日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 133
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Patients who have requested not to participate in this study based on the published information. 2.Patients who are currently participating or will participate in clinical research involving interventions related to pharmacotherapy. 3.Other patients who are judged ineligible by the principal investigator.
研究者
相似试验
已完成
2 期
SAVANNAHCarcinomaJPRN-jRCT2080224881AstraZeneca KK23
招募中
4 期
Efficacy study of osimertinib in treatment-naïve patients with EGFR mutant NSCLC according to TP53 mutational status (TEMPLE-2)2024-517424-18-00Fondazione Policlinico Universitario Agostino Gemelli IRCCS54
进行中（未招募）
2 期
A Phase 2 Study of Osimertinib in combination with Platinum-pemetrexed in patients with EGFR-mutated Advanced non-small cell Lung cancer.on-squamous non-small cell lung cancerJPRN-jRCTs031180226Kobayashi Kunihiko66
进行中（未招募）
1 期
Exploring the theragnostic value of osimertinib in EGFR-mutated lung cancer (THEROS) - A multicentric phase II study in patients with TKI-resistant EGFR-mutated lung cancer exhibiting early metabolic response to osimertinibon-small-cell lung cancer (NSCLC)MedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-005121-21-DEniversitätsklinikum Essen20
进行中（未招募）
2 期
First-Line Osimertinib for Poor Performance Status Patients with EGFR Mutant Non-Small Cell Lung Canceron-small cell lung cancerJPRN-jRCTs041200100Katsuhiko Naoki30